A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic Profiles and Food Effect of CS32582 Capsules

PHASE1CompletedINTERVENTIONAL

Enrollment

112

Participants

Timeline

Start Date

March 28, 2024

Primary Completion Date

November 27, 2024

Study Completion Date

November 27, 2024

Conditions

Healthy

Interventions

DRUG

CS32582 capsule

Participants receive CS32582 orally single or multiple doses

DRUG

Placebo capsule

Participants receive placebo matching CS32582 orally single or multiple doses

Trial Locations (1)

Zhongshan Hospital Affiliated to Fudan University, Shanghai